Warning: The NCBI web site requires JavaScript to function. more...
Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge.
Commander NJ, Brewer JM, Wren BW, Spencer SA, Macmillan AP, Stack JA.
Genet Vaccines Ther. 2010 Jul 16;8:5.
Related citations
[Novel vaccines against M. tuberculosis].
Okada M.
Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.
The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes.
Commander NJ, Spencer SA, Wren BW, MacMillan AP.
Vaccine. 2007 Jan 2;25(1):43-54. Epub 2006 Aug 4.
Evaluation of immunogenicity and protective activity in BALB/c mice of the 25-kDa major outer-membrane protein of Brucella melitensis (Omp25) expressed in Escherichia coli.
Bowden RA, Cloeckaert A, Zygmunt MS, Dubray G.
J Med Microbiol. 1998 Jan;47(1):39-48.
TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D.
PLoS Negl Trop Dis. 2011 Jun;5(6):e1204. doi: 10.1371/journal.pntd.0001204. Epub 2011 Jun 14.
Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis.
Edmonds MD, Cloeckaert A, Elzer PH.
Vet Microbiol. 2002 Sep 2;88(3):205-21.
Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.
Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH.
Infect Immun. 2005 Dec;73(12):8079-88.
A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.
Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH.
Infect Immun. 2005 Oct;73(10):6537-46.
Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J.
J Immunol. 2005 May 15;174(10):6292-8.
Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration.
Hattori Y, Kawakami S, Lu Y, Nakamura K, Yamashita F, Hashida M.
J Gene Med. 2006 Jul;8(7):824-34.
Microneedle-based vaccines.
Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK.
Curr Top Microbiol Immunol. 2009;333:369-93. Review.
The 'co-delivery' approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates.
Laing P, Bacon A, McCormack B, Gregoriadis G, Frisch B, Schuber F.
J Liposome Res. 2006;16(3):229-35.
Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells.
Muñoz-Montesino C, Andrews E, Rivers R, González-Smith A, Moraga-Cid G, Folch H, Céspedes S, Oñate AA.
Infect Immun. 2004 Apr;72(4):2081-7.
Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH.
Intervirology. 2006;49(3):144-51.
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG.
Infect Immun. 2002 Jun;70(6):2828-36.
Liposome-mediated DNA vaccination: the effect of vesicle composition.
Perrie Y, Frederik PM, Gregoriadis G.
Vaccine. 2001 Apr 30;19(23-24):3301-10.
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA, Neelapu SS, Kwak LW, Biragyn A.
Haematologica. 2002 Sep;87(9):989-1001. Review.
Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines.
Carstens MG, Camps MG, Henriksen-Lacey M, Franken K, Ottenhoff TH, Perrie Y, Bouwstra JA, Ossendorp F, Jiskoot W.
Vaccine. 2011 Jun 24;29(29-30):4761-70. Epub 2011 May 10.
Major outer membrane proteins of Brucella spp.: past, present and future.
Cloeckaert A, Vizcaíno N, Paquet JY, Bowden RA, Elzer PH.
Vet Microbiol. 2002 Dec 20;90(1-4):229-47.
Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.
Rosada RS, de la Torre LG, Frantz FG, Trombone AP, Zárate-Bladés CR, Fonseca DM, Souza PR, Brandão IT, Masson AP, Soares EG, Ramos SG, Faccioli LH, Silva CL, Santana MH, Coelho-Castelo AA.
BMC Immunol. 2008 Jul 22;9:38.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on